Aquestive Therapeutics, Inc. (AQST)
NASDAQ: AQST · Real-Time Price · USD
2.720
-0.220 (-7.48%)
Mar 13, 2025, 4:00 PM EDT - Market closed
Aquestive Therapeutics Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for Aquestive Therapeutics stock have an average target of 10.57, with a low estimate of 7.00 and a high estimate of 17. The average target predicts an increase of 288.60% from the current stock price of 2.72.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Aquestive Therapeutics stock from 7 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 5 | 5 | 6 | 6 | 6 | 5 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 8 | 8 | 8 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +267.65% | Mar 10, 2025 |
| Lake Street | Lake Street | Strong Buy Maintains $10 → $8 | Strong Buy | Maintains | $10 → $8 | +194.12% | Mar 7, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +267.65% | Dec 20, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Initiates $17 | Buy | Initiates | $17 | +525.00% | Dec 17, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +267.65% | Nov 11, 2024 |
Financial Forecast
Revenue This Year
54.01M
from 57.56M
Decreased by -6.17%
Revenue Next Year
73.30M
from 54.01M
Increased by 35.72%
EPS This Year
-0.62
from -0.51
EPS Next Year
-0.54
from -0.62
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 65.1M | 92.8M | 158.6M | ||
| Avg | 54.0M | 73.3M | 140.2M | ||
| Low | 41.5M | 45.1M | 124.1M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 13.1% | 71.9% | 116.3% | ||
| Avg | -6.2% | 35.7% | 91.3% | ||
| Low | -28.0% | -16.5% | 69.3% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.50 | -0.27 | -0.09 | ||
| Avg | -0.62 | -0.54 | -0.09 | ||
| Low | -0.76 | -0.71 | -0.09 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.